Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Drops By 35.8%

Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 312,900 shares, a drop of 35.8% from the December 31st total of 487,400 shares. Approximately 2.0% of the company's stock are short sold. Based on an average daily volume of 413,300 shares, the days-to-cover ratio is currently 0.8 days.

Neuronetics Stock Down 9.1 %

STIM stock traded down $0.31 on Friday, hitting $3.10. 901,473 shares of the company's stock were exchanged, compared to its average volume of 1,181,973. The firm has a 50 day moving average price of $1.69 and a two-hundred day moving average price of $1.29. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.87 and a current ratio of 3.16. Neuronetics has a 12-month low of $0.52 and a 12-month high of $5.07. The stock has a market cap of $94.09 million, a P/E ratio of -2.52 and a beta of 2.11.

Institutional Investors Weigh In On Neuronetics

Large investors have recently modified their holdings of the business. Renaissance Technologies LLC grew its position in Neuronetics by 124.5% during the 2nd quarter. Renaissance Technologies LLC now owns 322,200 shares of the company's stock worth $580,000 after purchasing an additional 178,700 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of Neuronetics by 55.5% during the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company's stock valued at $187,000 after buying an additional 87,816 shares during the last quarter. Landscape Capital Management L.L.C. acquired a new position in shares of Neuronetics in the 3rd quarter valued at about $53,000. GSA Capital Partners LLP boosted its stake in shares of Neuronetics by 64.5% in the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company's stock worth $60,000 after buying an additional 30,837 shares during the last quarter. Finally, David J Yvars Group grew its holdings in Neuronetics by 47.1% during the fourth quarter. David J Yvars Group now owns 46,325 shares of the company's stock worth $75,000 after acquiring an additional 14,825 shares during the period. Hedge funds and other institutional investors own 53.59% of the company's stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.